Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients.
D000450:Aldosterone / Q000097:blood / Q000652:urine; D000806:Angiotensin-Converting Enzyme Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000201:enzymology*; D000451:Mineralocorticoid Receptor Antagonists; D011188:Potassium / Q000378:metabolism; D012083:Renin / Q000097:blood; D012964:Sodium / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000494:pharmacology*; D000092502:Renin Inhibitors
D000450:Aldosterone; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D011188:Potassium; D012083:Renin; D012964:Sodium; D013438:Sulfhydryl Compounds; D000092502:Renin Inhibitors